Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.160
-0.020 (-0.92%)
Jul 22, 2026, 4:00 PM EDT - Market closed
Aytu BioPharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 56.6 | 66.38 | 65.18 | 107.4 | 96.67 | 65.63 | |
Revenue Growth (YoY) | -14.04% | 1.84% | -39.31% | 11.10% | 47.29% | 137.52% |
Cost of Revenue | 19.94 | 20.55 | 16.13 | 40.77 | 44.39 | 36.43 |
Gross Profit | 36.66 | 45.83 | 49.05 | 66.63 | 52.28 | 29.2 |
Selling, General & Admin | 40.69 | 38.29 | 42.04 | 70.08 | 69.88 | 55.81 |
Depreciation & Amortization Expenses | 2.65 | 3.68 | 3.68 | 4.79 | 5.84 | 6.01 |
Research & Development | 0.22 | 1.33 | 2.77 | 4.1 | 12.66 | 5.62 |
Other Operating Expenses | - | 10.36 | 2.16 | 6.67 | 77.11 | 20.63 |
Total Operating Expenses | 43.56 | 53.66 | 50.65 | 85.64 | 165.5 | 88.07 |
Operating Income | -4.06 | -7.83 | -1.59 | -17.07 | -109.91 | -58.87 |
Interest Expense | -2.24 | -3.7 | -5.06 | -4.96 | - | - |
Other Non-Operating Income (Expense) | -16.27 | -2.22 | -0.59 | 4.98 | -0.59 | 1.68 |
Total Non-Operating Income (Expense) | -18.51 | -5.92 | -5.65 | 0.01 | -0.59 | 1.68 |
Pretax Income | -33.67 | -13.75 | -10.38 | -17.05 | -108.89 | -58.03 |
Provision for Income Taxes | -0.45 | -0.44 | -2.14 | - | -0.11 | 0.26 |
Net Income | -34.12 | -14.18 | -12.52 | -17.05 | -108.78 | -58.29 |
Earnings From Discontinued Operations | 0.06 | 0.62 | -3.32 | - | - | - |
Net Income to Common | -34.06 | -13.56 | -15.84 | -17.05 | -108.78 | -58.29 |
Shares Outstanding (Basic) | 9 | 6 | 6 | 3 | 1 | 1 |
Shares Outstanding (Diluted) | 12 | 6 | 6 | 3 | 1 | 1 |
Shares Change (YoY) | 49.05% | 13.39% | 65.81% | 127.22% | 75.54% | 270.57% |
EPS (Basic) | -4.29 | -2.16 | -2.86 | -5.11 | -74.01 | -69.60 |
EPS (Diluted) | -4.58 | -2.16 | -2.86 | -5.11 | -74.01 | -69.60 |
Free Cash Flow | 1.64 | -2.17 | -1.72 | -5.13 | -28.82 | -25.96 |
Free Cash Flow Per Share | 0.14 | -0.34 | -0.31 | -1.54 | -19.61 | -31.01 |
Gross Margin | 64.78% | 69.04% | 75.26% | 62.04% | 54.08% | 44.49% |
Operating Margin | -7.18% | -11.79% | -2.44% | -15.89% | -113.69% | -89.70% |
Profit Margin | -60.28% | -21.36% | -19.21% | -15.88% | -112.53% | -88.81% |
FCF Margin | 2.90% | -3.26% | -2.63% | -4.78% | -29.82% | -39.56% |
EBITDA | -1.26 | -2.45 | 5.13 | -8.25 | -99.76 | -49.67 |
EBITDA Margin | -2.22% | -3.69% | 7.88% | -7.68% | -103.20% | -75.68% |
EBIT | -4.06 | -7.83 | -1.59 | -17.07 | -109.91 | -58.87 |
EBIT Margin | -7.18% | -11.79% | -2.44% | -15.89% | -113.69% | -89.70% |
Effective Tax Rate | 1.33% | 3.18% | 20.64% | 0.00% | 0.10% | -0.45% |